Skip to content

Clinical trials

Triple Negative Breast Neoplasms trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Triple Negative Breast Neoplasms Clear all

1,195 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20073
20089
200911
201027
201124
201220
201323
201423
201548
201665
201782
201872
201987
202084
202188
202293
202381
2024117
2025105
2026118

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting306
Completed296
Terminated154
Active, not recruiting144
Unknown status129
Not yet recruiting95
Withdrawn52
Suspended9
No longer available4
Enrolling by invitation4
Available1
Approved for marketing1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fudan University62
National Cancer Institute (NCI)45
M.D. Anderson Cancer Center28
Novartis Pharmaceuticals21
AstraZeneca14
Merck Sharp & Dohme LLC14
City of Hope Medical Center11
Gilead Sciences11
Pfizer11
AbbVie10

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Triple Negative Breast Neoplasms1,195
Breast Neoplasms468
Carcinoma, Non-Small-Cell Lung196
Ovarian Neoplasms134
Squamous Cell Carcinoma of Head and Neck102
Neoplasm Metastasis93
Colorectal Neoplasms91
Melanoma90
Carcinoma, Renal Cell83
Endometrial Neoplasms76

Trials

Showing 51 to 75 of 1,195. Each trial links to its page on Pharma Observatory.

1,095 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.